US Patent Issued to Sumitomo Pharma Switzerland, Takeda Pharmaceutical on June 24 for "Crystalline forms of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-dpyrimidin-6-yl)phenyl)-N'-methoxyurea" (American, Japanese Inventors)

ALEXANDRIA, Va., June 25 -- United States Patent no. 12,338,249, issued on June 24, was assigned to Sumitomo Pharma Switzerland GmbH (Basel, Switzerland) and Takeda Pharmaceutical Co. Ltd. (Osaka, Japan).

"Crystalline forms of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-dpyrimidin-6-yl)phenyl)-N'-methoxyurea" was invented by Michael Thomas Brandl (Redwood City, Calif.), Patricia Andres (Bend, Ore.), Petinka I. Vlahova (West Lafayette, Ind.) and Tsuyoshi Sasaki (Osaka, Japan).

According to the abstract* released by the U.S. Patent & Trademark Office: "This disclosure relates to novel crystalline forms of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6...